Several drugs available in kidney disease have also been shown to be partially contribute to the activation of the sirt1, such as sodium glucose co-transporter two inhibitors (Packer, 2020), angiotensin-converting enzyme inhibitor (enalapril) (Veitch et al., 2021), angiotensin II receptor blocker (olmesartan) (Gu et al., 2016), and statins (Khayatan et al., 2022). This evidence concerns the gene ACE and kidney disorder.